home / stock / lkysf / lkysf news


LKYSF News and Press, Rojo Resources Ltd From 05/25/21

Stock Information

Company Name: Rojo Resources Ltd
Stock Symbol: LKYSF
Market: OTC
Website: numinus.ca

Menu

LKYSF LKYSF Quote LKYSF Short LKYSF News LKYSF Articles LKYSF Message Board
Get LKYSF Alerts

News, Short Squeeze, Breakout and More Instantly...

LKYSF - Psychedelic Drug Market Has Become a Billion Dollar Industry As Acceptable Treatments Expand

Palm Beach, FL – May 25, 2021 – Recently, the use of psychedelics is evolving for the treatment of a variety of mental illnesses, including anxiety, depression, post-traumatic stress disorder and other related uses. Some psychedelic drugs are extracted from plants or mushrooms...

LKYSF - Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation

Experienced executives fill senior roles in business development, M&A, clinic operations and design, and corporate communications VANCOUVER, BC, May 13, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Compa...

LKYSF - Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application Canada NewsWire Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial VANCOUVER, BC ,...

LKYSF - Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD Canada NewsWire Numinus and Multidisciplinary Association for Psychedelic Studies collaboration will conduct follow-on Compassionate Acces...

LKYSF - Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC

Events subsequent to quarter-end include $40.25 million financings and Phase 1 clinical trial VANCOUVER, BC, April 29, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care...

LKYSF - Numinus Wellness reports FQ2 results

Numinus Wellness (LKYSF): FQ2 Net loss of C$4.2M.Revenue of C$0.23M (-11.5% Y/Y)Press Release For further details see: Numinus Wellness reports FQ2 results

LKYSF - MNMD Stock: A MindMed Buzz Kill as the Psychedelic Shares Tank on First Day of Trading

InvestorPlace - Stock Market News, Stock Advice & Trading Tips MindMed (NASDAQ: MNMD ) stock isn’t doing so hot with shares taking a beating on the first day of trading at their new home. Source: local_doctor / Shutterstock.com MNMD stock joined the Nasdaq Exchang...

LKYSF - Another psychedelics company goes public on U.S. exchange

New York-based MindMed will begin trading on the Nasdaq today, becoming the second psychedelic company ever to go public on a major American exchange. Shroom drug developer Compass Pathways (CMPS) debuted only six months ago, while another "drug growth platform,"called Atai Life Sciences, fil...

LKYSF - MNMD Stock: 9 Things to Know Before MindMed Hits the Nasdaq on April 27

InvestorPlace - Stock Market News, Stock Advice & Trading Tips MindMed (OTCMKTS: MMEDF ) stock has been climbing recently in anticipation of its uplisting on the Nasdaq Exchange this week, where it will trade as MNMD stock. The company’s announcement that it will be h...

LKYSF - Numinus Announces Listing of Warrants and Change of Trading Symbol for Previously Listed Warrants

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, April 26, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company“), a menta...

Previous 10 Next 10